Actively Recruiting
Study Evaluating Sonrotoclax Alone and With Dexamethasone Plus Carfilzomib, Daratumumab, or Pomalidomide for Patients With Relapsed or Refractory Multiple Myeloma and t1114
Led by BeOne Medicines · Updated on 2026-10-26
246
Participants Needed
74
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating sonrotoclax, alone and in combination with dexamethasone, carfilzomib, daratumumab, and pomalidomide, in patients with relapsed or refractory multiple myeloma who have a specific chromosomal translocation t1114. The study aims to assess the safety, tolerability, and effectiveness of sonrotoclax in this group. This research is sponsored by BeOne Medicines and is conducted as a Phase 1b2 interventional trial. The study includes dose-escalation and de-escalation phases to find the maximum tolerated dose of sonrotoclax with each combination. Participants may receive sonrotoclax orally every day, dexamethasone once weekly by mouth or intravenously, carfilzomib intravenously weekly, daratumumab subcutaneously weekly, or pomalidomide orally daily. There are up to seven expansion groups to further evaluate safety and effectiveness of sonrotoclax alone or combined with the other drugs. Participants will be monitored for dose-limiting toxicities and adverse events throughout the treatment periods. Researchers will assess response rates and durability of response over about four years. Blood and urine tests will measure disease markers, and organ function will be checked. Safety monitoring continues up to 30 days after last dose, and long-term outcomes like progression-free and overall survival will be evaluated. The trial will continue until November 2026.
CONDITIONS
Brief Title
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Research Team
B
BeOne Medicines
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here